



**TO THE SPANISH NATIONAL SECURITIES MARKET COMMISSION
(COMISIÓN NACIONAL DEL MERCADO DE VALORES)**

Madrid, 24 June 2024

In compliance with the information duties provided for in article 227 of the Law 6/2023, of 17 March, on the Securities Markets and Investment Services, Laboratorios Farmacéuticos ROVI, S.A. (hereinafter, “**ROVI**” or the “**Company**”) hereby discloses to the Spanish National Securities Market Commission the following

OTHER RELEVANT INFORMATION

- I. The Ordinary General Shareholders’ Meeting held today, 24 June 2024, on first call, has approved all the proposed resolutions submitted by the Board of Directors to its approval and summarized as follows:
 1. Approval of the individual financial statements of the Company and of the consolidated financial statements of the Company with its subsidiaries, as well as of the individual management report of the Company and the consolidated management report of the Company with its subsidiaries, all for the financial year ended 31 December 2023.
 2. Approval of the statement of non-financial information included in the consolidated management report of the Company with its subsidiaries for the year ended 31 December 2023.
 3. Approval of the proposal for the application of the individual profit for the year ended 31 December 2023 and the proposal for the final dividend, which includes the payment of a fixed dividend of 1.1037 euros gross per share entitled to receive it, which would imply the distribution of an amount approximately equivalent to 35% of the 2023 consolidated profit attributed to the parent company (*sociedad dominante*). The abovementioned amount will be paid on 10 July 2024.
 4. Approval of the management work and performance of the Board of Directors during the year ended 31 December 2023.
 5. Approval of the re-election of Ms. Fátima Báñez García as external independent director for the term established in the bylaws.
 6. Approval of the maximum annual remuneration of the members of the Board of Directors in their capacity as such for the 2024 financial year.
 7. Approval of the remuneration policy of the Board members for the period 2025-2027.
 8. Approval of the Long-Term Incentive Plan 2025-2027 through the delivery of shares of the Company, if applicable, to the executive directors of the Company.

9. Approval of a reduction of the share capital through the cancellation of a maximum of 3,347,619 shares of treasury stock, and the consequent amendment of Article 5 of the Company's bylaws.
10. Re-election of the auditors of the Company and its consolidated group for financial year 2024, KPMG Auditores, S.L.
11. Delegation of powers to formalise and register the resolutions adopted by the General Shareholders' Meeting and to carry out the mandatory filing of the financial statements.
12. Approval of the annual report on Directors' remuneration with an advisory vote.

The General Shareholders Meeting was also informed of the amendments to the Regulations of the Board of Directors of the Company resulting from the revision of the Regulations of the Audit Committee and the incorporation of certain improvements of a technical nature.

The text of the resolutions approved by the General Shareholders Meeting and the outcome of the voting will be published on the Company's website within the next five days.

- II. The Board of Directors of ROVI has agreed to re-elect Ms. Fátima Báñez García as member of the Appointments and Remuneration Committee and of the Audit Committee for a term of four years.

Mr. Juan López-Belmonte Encina

Chairman of the Board of Directors and Chief Executive Officer (*Consejero Delegado*)
Laboratorios Farmacéuticos ROVI, S.A.